Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

That scenario is if either of the one dose and done arms exceed 90% efficacy with no AEs. That's only for ABSSI. Oral, ocular and aural B are reformulations as a mouthwash, eyedrop, and ear drop, so those would be separate licenses and if a Pharma wanted the platform, the minimum price triples, which few pharmas would consider very seriously.

"Given those perimeters: upfront >$50 million; total benchmarks >$400 million; royalties >17%"

Consequently, for the platform: upfront >$150 million; total benchmarks >$1.2 billion; royalties still >17%

Not many pharmas will go 1.4 billion andmore than 17% for a mostly unproven platform; however, one pharma might given ABSSSI success that would further validate all preclinical to clinical data. B is another one of those drugs where preclinical results have closely aligned with early clinical data, so far.